Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b/2 Trial of Tisotumab Vedotin (HuMax-TF-ADC) Alone and in Combination in Recurrent or Stage IVB Cervical Cancer
2023-508832-68-00Phase 2Completed
- Sponsor
- Genmab
- Start
- Apr 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 8
01
Overview
Phase 2, open-label trial of tisotumab vedotin in Cervical Cancer (CC) (8 arms), sponsored by Genmab. Primary endpoints: Dose escalation safety endpoints and Objective Response Rate (dose expansion). Started Apr 2024; status: completed.
02
Drugs
tisotumab vedotin
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on 2023-508832-68-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508832-68-00.